Charterhouse-backed Cooper acquired Laboratoires Diepharmex.

Synopsis

Cooper, a French pharmaceutical company backed by London-based private equity investment firm Charterhouse Capital Partners, acquired Laboratoires Diepharmex, a pharmaceutical company in Geneva, Switzerland. Financial terms were not disclosed. For Cooper, owned by Charterhouse since 2015, this new acquisition grants the opportunity to seize an iconic brand in hygiene and ear care.

Principals

target

Laboratoires Diepharmex

bidder

Cooper Consumer Health

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (1)

benjamin rousselot

CEO at LABORATOIRES DIEPHARMEX

Manager

target

Deal

n/a

Total Value

Bidder Team (2)

cedric barthelemy

CHARTERHOUSE CAPITAL PARTNERS

Investor

bidder

Deals

£ 3.75 B

Total Value

fabrice georget

CHARTERHOUSE CAPITAL PARTNERS

Investor

bidder

Deals

£ 3.86 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy